SARS-CoV-2 neutralizing antibody development strategies

Authors : Bertan Koray BALCİOGLU, Melis Denizci ONCU, Hasan Umit OZTURK, Fatima YUCEL, Filiz KAYA, Muge SERHATLİ, Hivda Ulbegi POLAT, Saban TEKİN, Aylin Ozdemir BAHADİR

Pages : 203-214

View : 23 | Download : 11

Publication Date : 2020-12-01

Article Type : Research Paper

Abstract :In December 2019 a novel coronavirus was detected in Wuhan City of Hubei Province-China. Owing to a high rate of transmission from human to human, the new virus called SARS-CoV-2 differed from others by its unexpectedly rapid spread. The World Health Organization insert ignore into journalissuearticles values(WHO); described the most recent coronavirus epidemic as a global pandemic in March 2020. The virus spread triggered a health crisis insert ignore into journalissuearticles values(the COVID-19 disease); within three months, with socioeconomic implications. No approved targeted-therapies are available for COVID-19, yet. However, it is foreseen that antibody-based treatments may provide an immediate cure for patients. Current neutralizing antibody development studies primarily target the S protein among the structural elements of SARS-CoV-2, which mediates the cell entry of the virus through the angiotensin converting enzyme 2 insert ignore into journalissuearticles values(ACE2); receptor of host cells. This review aims to provide some of the neutralizing antibody development strategies for SARS-CoV-2 and in vitro and in vivo neutralization assays.
Keywords : SARS CoV 2, COVID 19, neutralizing antibodies, human monoclonal antibody, display technologies, human scFv, neutralizing assays, animal models